Langsheng Pharmaceutical Completes Over RMB 1 Billion Series C Financing to Strengthen Leadership in Reproductive Health Sector

VCBeat News has learned that Guangzhou Regenex Pharmaceuticals, Ltd. recently successfully completed a Series C financing round exceeding RMB 100 million. The round was jointly participated in by Fortune Capital, Chuangyu Investment, Guangzhou Industrial Investment Holdings Group, and GF Xinde.The primary use of the funds raised is directed towardProduct R&D, market expansion, and production line optimization to strengthen the company’s leading position in the reproductive health industry.Regenex Pharmaceuticals stated that it will continue to amplify the functional value of its capital, working jointly to address population challenges such as promoting fertility and mitigating aging, thereby achieving significant advancements in the field of human reproductive health.

Since its establishment in 2003, Regenex Pharmaceuticals has traversed two decades, consistently upholding its corporate mission of “making human reproduction healthier.” The company actively responds to the national policy on “promoting fertility” and safeguards the nation’s reproductive capacity. In the field of reproductive health, Regenex Pharmaceuticals owns multiple brands, including Chiwei, Danmei, Chilu, Hongma, and Sumi. In 2014, “Chiwei” received the special Grand Prize from the Bill & Melinda Gates Foundation’s “Grand Challenges Explorations” program. Centered on the brand philosophy of “caring for women’s health,” this product series has garnered widespread acclaim from consumers.

As a pharmaceutical enterprise deeply rooted in China’s reproductive health sector, Regenex Pharmaceuticals has been consistently committed to scientific research and development. To date, the company holds 52 valid patents, including 25 invention patents. Its product pipeline comprises more than 50 medical devices and over 40 pharmaceutical products, covering a comprehensive range of areas such as family planning, perinatal care, women’s healthcare, infant and child healthcare, prevention and treatment of infertility, prevention and control of sexually transmitted diseases (STDs), and in vitro diagnostics (IVD).

Leveraging its robust capabilities in the research and development of various pharmaceuticals and medical devices, Regenex Pharmaceuticals, Ltd. was honored with the title of “Guangdong Province Specialized, Refined, Distinctive, and Innovative SME” in 2022. In September of the same year, Regenex stood out among more than 12,000 high-tech enterprises across the city to be included in the “2022 Guangzhou Top 100 High-Tech Enterprises Proposed for Listing,” which is subject to annual dynamic management to cultivate the “Guangzhou High-Tech Enterprise Tier” in the capital market. This recognition fully affirms Regenex’s strengths in corporate scale, economic performance, and scientific research, while also demonstrating that the company’s development has been acknowledged by Guangzhou’s capital market.

Regenex Pharmaceuticals has long been committed to disseminating accurate knowledge about sexual health to the general public. The company established the Regenex Institute of Reproductive Health, which provides science-based education to the public across three key areas: female reproductive health, male reproductive health, and assisted reproductive health. This platform enables the public to gain a comprehensive understanding of reproductive health-related knowledge and information.

In 2022, to better convey healthy and correct concepts of gender relations to young people, Regenex Pharmaceuticals and Chiwei jointly co-sponsored the 14th National College Student Advertising Art Competition (hereinafter referred to as the "National Ad Competition"), which is one of the largest-scale national humanities competitions for college students with significant social influence to date. The National Ad Competition covers numerous higher education institutions, involves a large number of participating teachers and students, features high-quality entries, and is widely welcomed by faculty members across universities. This year, Regenex Pharmaceuticals once again partnered with the National Ad Competition to release corporate-themed challenges and launch online promotional cloud lectures, aiming to disseminate healthy and accurate sexual health knowledge among college students, reduce the incidence of unintended pregnancies and sexually transmitted diseases in the younger population, strengthen college students’ sense of social responsibility, and promote the youth-oriented dissemination of sexual health education.

The World Health Organization defines reproductive health as a state of complete physical, mental, and social well-being in all matters relating to the reproductive system and to its functions and processes throughout the life course. This encompasses health at the physiological, psychological, and social levels, including disease prevention and control as well as sexual health across the entire human lifespan. On October 16, 2022, the report to the 20th National Congress of the Communist Party of China also proposed “advancing the Healthy China initiative, prioritizing the protection of people’s health in strategic development, establishing a policy framework to support childbirth, and implementing a national strategy to actively respond to population aging.”

“Pro-natalist policies” serve as proactive measures to address population aging and have a profound impact on sustainable social development. Regenex Pharmaceuticals, Ltd. provides scientifically sound and rational products and services in the field of reproductive health, which help enhance public willingness to have children and ensure reproductive protection. By making corporate efforts and demonstrating responsibility in combating population aging and boosting fertility rates, the company fulfills significant social significance and corporate social responsibility.

The successful completion of this financing round fully demonstrates the market’s confidence in the development of Regenex Pharmaceuticals and the promising prospects of the reproductive health sector. On its future journey, Regenex Pharmaceuticals will continue to focus on advancing human reproductive health, deeply cultivating various segments including pre- and post-natal care, infertility treatment, male and female reproductive system health, at-home early screening and testing, reproductive tract maintenance, and contraception methods for special circumstances. Regenex Pharmaceuticals also stated that it will remain committed to sustainable corporate development, leverage its strength and influence, strive for breakthroughs in the reproductive health field, and work towards realizing its blueprint for an initial public offering (IPO).

Fortune Capital is one of the most influential venture capital and private equity firms in China. Over the years, it has consistently ranked on authoritative lists due to its outstanding performance, maintaining a top-three position among domestic VC/PE firms for nearly a decade. With assets under management totaling RMB 50 billion, the firm has invested in more than 730 companies, including numerous well-known publicly listed enterprises. Adhering to the philosophy of long-term, professional, and value investing, Fortune Capital focuses on sectors such as information technology and healthcare, with branch offices established in 21 cities across China. By building strategic alliances and providing value-added services, the firm aims to empower partners, foster collaboration, and achieve mutual success. Meanwhile, it is committed to becoming a trusted partner that meets the needs of investors, entrepreneurs, and employees, making positive contributions to China’s economic transformation, upgrading, and innovative development.

Chuangyu Investment is positioned as a boutique investment bank, currently managing over RMB 5 billion in assets and boasting a professional team of more than 30 experts in investment research and mergers and acquisitions. Over the past two years, ten portfolio companies have successfully gone public or passed regulatory review, two are undergoing IPO scrutiny, and eleven are under guidance pending filing. In 2022, the firm was honored with awards including “Top 50 Influential PE Investment Institutions in China” by the China Venture Capital Research Institute and “Top 30 Best Investment Institutions in the Guangdong-Hong Kong-Macao Greater Bay Area” by CVSource.

Guangzhou Industrial Investment Holding Group Co., Ltd. (hereinafter referred to as “Guangzhou Industrial Investment Group”) was formerly known as Guangzhou State-owned Assets Development Holding Co., Ltd., the first state-owned capital investment and operation platform established in Guangzhou in 2016. Approved by the Municipal Committee of the Communist Party of China and the Guangzhou Municipal People’s Government, it was restructured and commenced operations on December 3, 2021.

Since its establishment, Guangzhou Industrial Investment Group has anchored itself in three core functional positions: a strategic investment and development platform, a state-owned equity holding platform, and a capital operation and management platform. Adhering to the investment philosophy of “Investing in Guangzhou, Investing in the Real Economy, and Investing in the Future,” the Group has embraced the mindsets of “patient capital” and “proactive investment promotion.” With the core mission of driving the extension, supplementation, strengthening, and expansion of Guangzhou’s industrial chains, it actively assumes the dual roles of an industrial investment bank and a capital operator. The Group focuses on key businesses including industrial investment, industrial park development, equity management, capital operations, and asset management. It is fully committed to serving the overall development of the Guangdong-Hong Kong-Macao Greater Bay Area, striving to build a first-class, market-oriented, professional, and international state-owned capital investment and operation platform.

GF Xinde Investment Management Co., Ltd. is a wholly-owned private equity fund subsidiary of GF Securities Co., Ltd., and ranks among the leading broker-affiliated private equity investment subsidiaries in China. Leveraging its outstanding professional capabilities, GF Xinde has consistently ranked at the forefront of industry lists published by Zero2IPO, CVSource, New Fortune, and China Securities Journal for many consecutive years. Adhering to the business philosophy of “investment-oriented and customer-first,” the company conducts forward-looking investment layouts based on in-depth industry research, with rigorous and pragmatic compliance and risk management integrated throughout its operations. Relying on the comprehensive advantages of its parent company, GF Securities Financial Group, as well as its own strategic management capabilities, GF Xinde is committed to providing post-investment value-added services that create comprehensive value for portfolio companies, thereby achieving mutual benefits for managers, investors, and portfolio companies. Currently, the funds raised and managed by the company span multiple industries, including healthcare, consumption upgrading, clean energy and intelligent manufacturing, and TMT, covering various fields such as private equity (PE) investment, venture capital (VC) investment, M&A investment, and special situation investment.